vs
DYNAVAX TECHNOLOGIES CORP（DVAX）与HERITAGE FINANCIAL CORP（HFWA）财务数据对比。点击上方公司名可切换其他公司
DYNAVAX TECHNOLOGIES CORP的季度营收约是HERITAGE FINANCIAL CORP的1.4倍（$94.9M vs $66.3M），HERITAGE FINANCIAL CORP净利率更高（33.5% vs 28.4%，领先5.1%），DYNAVAX TECHNOLOGIES CORP同比增速更快（17.7% vs 16.3%），HERITAGE FINANCIAL CORP自由现金流更多（$85.7M vs $32.6M），过去两年DYNAVAX TECHNOLOGIES CORP的营收复合增速更高（30.6% vs 16.8%）
Dynavax Technologies Corp是一家处于商业化阶段的生物制药企业，专注于研发和生产针对传染病的创新疫苗及免疫疗法，核心上市产品为成人乙肝疫苗Heplisav-B，主要市场覆盖北美与欧洲，同时拥有多款针对未满足公共卫生需求的在研产品。
总部位于美国华盛顿州的区域性金融控股公司，面向太平洋西北地区的当地社群提供服务，核心业务涵盖商业与零售银行服务，包含存款产品、中小企业贷款、住房抵押贷款、个人信贷及财富管理解决方案，核心客群为中小微企业及个人客户。
DVAX vs HFWA — 直观对比
营收规模更大
DVAX
是对方的1.4倍
$66.3M
营收增速更快
DVAX
高出1.4%
16.3%
净利率更高
HFWA
高出5.1%
28.4%
自由现金流更多
HFWA
多$53.1M
$32.6M
两年增速更快
DVAX
近两年复合增速
16.8%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.9M | $66.3M |
| 净利润 | $26.9M | $22.2M |
| 毛利率 | — | — |
| 营业利润率 | 22.4% | 38.7% |
| 净利率 | 28.4% | 33.5% |
| 营收同比 | 17.7% | 16.3% |
| 净利润同比 | 53.0% | 86.4% |
| 每股收益（稀释后） | $0.21 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DVAXHFWA
| Q4 25 | — | $66.3M | ||
| Q3 25 | $94.9M | $65.7M | ||
| Q2 25 | $95.4M | $56.5M | ||
| Q1 25 | $68.2M | $57.6M | ||
| Q4 24 | $72.0M | $57.1M | ||
| Q3 24 | $80.6M | $54.8M | ||
| Q2 24 | $73.8M | $56.4M | ||
| Q1 24 | $50.8M | $48.6M |
净利润DVAXHFWA
| Q4 25 | — | $22.2M | ||
| Q3 25 | $26.9M | $19.2M | ||
| Q2 25 | $18.7M | $12.2M | ||
| Q1 25 | $-96.1M | $13.9M | ||
| Q4 24 | $7.0M | $11.9M | ||
| Q3 24 | $17.6M | $11.4M | ||
| Q2 24 | $11.4M | $14.2M | ||
| Q1 24 | $-8.7M | $5.7M |
营业利润率DVAXHFWA
| Q4 25 | — | 38.7% | ||
| Q3 25 | 22.4% | 34.0% | ||
| Q2 25 | 15.1% | 25.6% | ||
| Q1 25 | -34.7% | 28.1% | ||
| Q4 24 | -2.3% | 28.6% | ||
| Q3 24 | 12.5% | 23.8% | ||
| Q2 24 | 7.0% | 28.4% | ||
| Q1 24 | -35.0% | 14.1% |
净利率DVAXHFWA
| Q4 25 | — | 33.5% | ||
| Q3 25 | 28.4% | 29.2% | ||
| Q2 25 | 19.6% | 21.6% | ||
| Q1 25 | -141.0% | 24.2% | ||
| Q4 24 | 9.8% | 20.9% | ||
| Q3 24 | 21.8% | 20.8% | ||
| Q2 24 | 15.4% | 25.1% | ||
| Q1 24 | -17.2% | 11.8% |
每股收益（稀释后）DVAXHFWA
| Q4 25 | — | $0.65 | ||
| Q3 25 | $0.21 | $0.55 | ||
| Q2 25 | $0.14 | $0.36 | ||
| Q1 25 | $-0.77 | $0.40 | ||
| Q4 24 | $0.07 | $0.34 | ||
| Q3 24 | $0.12 | $0.33 | ||
| Q2 24 | $0.08 | $0.41 | ||
| Q1 24 | $-0.07 | $0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $160.2M | $233.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $534.1M | $921.5M |
| 总资产 | $946.5M | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DVAXHFWA
| Q4 25 | — | $233.1M | ||
| Q3 25 | $160.2M | $245.5M | ||
| Q2 25 | $99.1M | $254.1M | ||
| Q1 25 | $51.7M | $248.7M | ||
| Q4 24 | $95.9M | $117.1M | ||
| Q3 24 | $119.3M | $175.6M | ||
| Q2 24 | $112.5M | $113.8M | ||
| Q1 24 | $132.0M | $189.6M |
股东权益DVAXHFWA
| Q4 25 | — | $921.5M | ||
| Q3 25 | $534.1M | $904.1M | ||
| Q2 25 | $494.2M | $888.2M | ||
| Q1 25 | $530.9M | $881.5M | ||
| Q4 24 | $596.8M | $863.5M | ||
| Q3 24 | $681.4M | $874.5M | ||
| Q2 24 | $642.8M | $850.5M | ||
| Q1 24 | $618.5M | $847.6M |
总资产DVAXHFWA
| Q4 25 | — | $7.0B | ||
| Q3 25 | $946.5M | $7.0B | ||
| Q2 25 | $918.4M | $7.1B | ||
| Q1 25 | $945.9M | $7.1B | ||
| Q4 24 | $986.3M | $7.1B | ||
| Q3 24 | $1.1B | $7.2B | ||
| Q2 24 | $1.0B | $7.1B | ||
| Q1 24 | $986.6M | $7.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.8M | $94.8M |
| 自由现金流经营现金流 - 资本支出 | $32.6M | $85.7M |
| 自由现金流率自由现金流/营收 | 34.4% | 129.1% |
| 资本支出强度资本支出/营收 | 1.3% | 13.8% |
| 现金转化率经营现金流/净利润 | 1.26× | 4.26× |
| 过去12个月自由现金流最近4个季度 | $80.5M | $149.0M |
8季度趋势，按日历期对齐
经营现金流DVAXHFWA
| Q4 25 | — | $94.8M | ||
| Q3 25 | $33.8M | $25.1M | ||
| Q2 25 | $23.4M | $22.5M | ||
| Q1 25 | $-19.6M | $19.3M | ||
| Q4 24 | $53.0M | $64.5M | ||
| Q3 24 | $19.5M | $24.2M | ||
| Q2 24 | $10.7M | $6.8M | ||
| Q1 24 | $-16.7M | $12.9M |
自由现金流DVAXHFWA
| Q4 25 | — | $85.7M | ||
| Q3 25 | $32.6M | $24.4M | ||
| Q2 25 | $22.0M | $20.9M | ||
| Q1 25 | $-23.6M | $18.1M | ||
| Q4 24 | $49.5M | $61.0M | ||
| Q3 24 | $18.1M | $23.2M | ||
| Q2 24 | $9.9M | $6.0M | ||
| Q1 24 | $-17.4M | $12.0M |
自由现金流率DVAXHFWA
| Q4 25 | — | 129.1% | ||
| Q3 25 | 34.4% | 37.1% | ||
| Q2 25 | 23.0% | 37.0% | ||
| Q1 25 | -34.6% | 31.4% | ||
| Q4 24 | 68.8% | 107.0% | ||
| Q3 24 | 22.5% | 42.4% | ||
| Q2 24 | 13.5% | 10.6% | ||
| Q1 24 | -34.3% | 24.7% |
资本支出强度DVAXHFWA
| Q4 25 | — | 13.8% | ||
| Q3 25 | 1.3% | 1.0% | ||
| Q2 25 | 1.5% | 2.8% | ||
| Q1 25 | 5.8% | 2.0% | ||
| Q4 24 | 4.8% | 6.1% | ||
| Q3 24 | 1.7% | 1.7% | ||
| Q2 24 | 1.1% | 1.5% | ||
| Q1 24 | 1.5% | 1.8% |
现金转化率DVAXHFWA
| Q4 25 | — | 4.26× | ||
| Q3 25 | 1.26× | 1.31× | ||
| Q2 25 | 1.25× | 1.84× | ||
| Q1 25 | — | 1.38× | ||
| Q4 24 | 7.52× | 5.41× | ||
| Q3 24 | 1.11× | 2.12× | ||
| Q2 24 | 0.94× | 0.48× | ||
| Q1 24 | — | 2.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
HFWA
暂无分部数据
